📊 BMRN Key Takeaways
Is Biomarin Pharmaceutical Inc. (BMRN) a Good Investment?
BioMarin maintains a fortress balance sheet with excellent liquidity and strong free cash flow generation (26.1% FCF margin), providing financial stability. However, net income declined 18.3% YoY despite 12.9% revenue growth, and critically low ROE (1.7%) and ROA (1.2%) reveal severe capital efficiency problems, suggesting operational headwinds or significant non-cash charges offsetting growth.
BioMarin shows solid fundamental quality with double-digit revenue growth, strong free cash flow generation, and an exceptionally strong balance sheet with low leverage and high liquidity. The main constraint is that earnings are not compounding as fast as revenue, with flat net income and declining diluted EPS, but overall financial health and cash generation remain strong.
Why Buy Biomarin Pharmaceutical Inc. Stock? BMRN Key Strengths
- Outstanding liquidity position (5.81x current ratio, 4.20x quick ratio) provides financial flexibility
- Strong free cash flow generation of $199.7M with 26.1% FCF margin conversion
- Healthy balance sheet with low leverage (0.23x debt-to-equity) and $2.2B cash reserves
- Solid revenue growth of 12.9% YoY in competitive pharmaceutical sector
- Strong interest coverage (13.5x) indicates minimal financial distress risk
- Revenue grew 12.9% year over year, indicating continued commercial expansion
- Free cash flow is robust at $724.96M with a strong 22.5% FCF margin
- Balance sheet strength is high, with $1.31B in cash, low debt/equity of 0.10x, and very strong liquidity ratios
BMRN Stock Risks: Biomarin Pharmaceutical Inc. Investment Risks
- Net income declined 18.3% YoY while revenue grew 12.9%, indicating margin compression or rising operating expenses
- Extremely low return on equity (1.7%) and return on assets (1.2%) suggest poor capital deployment efficiency
- EPS declined 18.6% YoY, worse than net income decline, potentially indicating share dilution or concentrated losses
- Pharma sector typically requires sustained R&D investment; unclear if current spending is generating future value
- Net income was flat despite higher revenue, suggesting margin scaling remains limited
- Diluted EPS fell 18.6% year over year, indicating weaker per-share earnings performance
- Return metrics remain modest, with ROE of 5.7% and ROA of 4.6%, which limits evidence of high capital efficiency
Key Metrics to Watch
- Operating expense ratio trend - key to understanding margin compression
- Product pipeline productivity and clinical trial progress to assess future revenue quality
- Free cash flow sustainability relative to capital expenditure obligations
- Return on equity trajectory - must improve from current 1.7% level
- Operating margin and net margin progression
- Diluted EPS growth relative to revenue growth
Biomarin Pharmaceutical Inc. (BMRN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 26.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 5.81x current ratio provides a solid financial cushion.
BMRN Profit Margin, ROE & Profitability Analysis
BMRN vs Healthcare Sector: How Biomarin Pharmaceutical Inc. Compares
How Biomarin Pharmaceutical Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biomarin Pharmaceutical Inc. Stock Overvalued? BMRN Valuation Analysis 2026
Based on fundamental analysis, Biomarin Pharmaceutical Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biomarin Pharmaceutical Inc. Balance Sheet: BMRN Debt, Cash & Liquidity
BMRN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biomarin Pharmaceutical Inc.'s revenue has grown significantly by 73% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.87 reflects profitable operations.
BMRN Revenue Growth, EPS Growth & YoY Performance
BMRN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $745.1M | $105.5M | $0.54 |
| Q3 2025 | $745.7M | -$30.7M | $-0.16 |
| Q2 2025 | $712.0M | $107.2M | $0.55 |
| Q1 2025 | $648.8M | $88.7M | $0.46 |
| Q3 2024 | $581.3M | $40.4M | $0.21 |
| Q2 2024 | $595.3M | $56.0M | $0.29 |
| Q1 2024 | $596.4M | $50.9M | $0.27 |
| Q3 2023 | $505.3M | -$6.7M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biomarin Pharmaceutical Inc. Dividends, Buybacks & Capital Allocation
BMRN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biomarin Pharmaceutical Inc. (CIK: 0001048477)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BMRN
What is the AI rating for BMRN?
Biomarin Pharmaceutical Inc. (BMRN) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BMRN's key strengths?
Claude: Outstanding liquidity position (5.81x current ratio, 4.20x quick ratio) provides financial flexibility. Strong free cash flow generation of $199.7M with 26.1% FCF margin conversion. ChatGPT: Revenue grew 12.9% year over year, indicating continued commercial expansion. Free cash flow is robust at $724.96M with a strong 22.5% FCF margin.
What are the risks of investing in BMRN?
Claude: Net income declined 18.3% YoY while revenue grew 12.9%, indicating margin compression or rising operating expenses. Extremely low return on equity (1.7%) and return on assets (1.2%) suggest poor capital deployment efficiency. ChatGPT: Net income was flat despite higher revenue, suggesting margin scaling remains limited. Diluted EPS fell 18.6% year over year, indicating weaker per-share earnings performance.
What is BMRN's revenue and growth?
Biomarin Pharmaceutical Inc. reported revenue of $766.2M.
Does BMRN pay dividends?
Biomarin Pharmaceutical Inc. does not currently pay dividends.
Where can I find BMRN SEC filings?
Official SEC filings for Biomarin Pharmaceutical Inc. (CIK: 0001048477) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BMRN's EPS?
Biomarin Pharmaceutical Inc. has a diluted EPS of $0.54.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BMRN a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Biomarin Pharmaceutical Inc. has a BUY rating with 76% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is BMRN stock overvalued or undervalued?
Valuation metrics for BMRN: ROE of 1.7% (sector avg: 15%), net margin of 13.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BMRN stock in 2026?
Our dual AI analysis gives Biomarin Pharmaceutical Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is BMRN's free cash flow?
Biomarin Pharmaceutical Inc.'s operating cash flow is $220.7M, with capital expenditures of $20.9M. FCF margin is 26.1%.
How does BMRN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 13.8% (avg: 12%), ROE 1.7% (avg: 15%), current ratio 5.81 (avg: 2).